Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer (ProSperACC-1)

Inclusion Criteria: Written informed consent Patient is able to understand and comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations Men aged 18 and above Earlier histologic diagnosis of prostatic adenocarcinoma Low risk of rapid disease progression, defined as: - PSA-detection Time (DT) > 1 year AND pathological International Society of Urological Pathology (ISUP) grade < 4 for men with prior radical prostatectomy or Interval to biochemical recurrence > 18 months and biopsy ISUP grade < 4 for men with prior radiation therapy Biochemical recurrence (BCR) in compliance with the following 3 conditions: after having finished last definitive treatment PSA ≥0.2 ng/mL or PSA > nadir + 2 ng/mL (after definitive RT), with two increasing PSA values prior to study treatment no distant metastasis upon PSMA- positron emission tomography (PET) imaging Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1 Male patients with partners of child-bearing potential, who are sexually active, must agree to the use of one highly effective form of contraception and one barrier method. This should be started from the signing of the informed consent and continue throughout period of taking study treatment and for 4 months after the last dose of study drug Adequate bone marrow, renal, and hepatic function defined by laboratory tests within 21 days prior to study treatment: Hemoglobin ≥ 9 g/dl (Transfusion of packed red blood cells prior to enrolment allowed) Neutrophil count ≥ 1,500/mm3 Platelet count ≥ 100,000/µl Bilirubin ≤ 1.5 x upper limit of normal (ULN) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN gamma-glutamyl-transferase (γ-GT) ≤ 2.5 x ULN prothrombin time (PT) - international normalised ratio (INR) / partial thromboplastin time (PTT) ≤ 1.5 x ULN Creatine kinase ≤ 2.5 x ULN Serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 ml/min Exclusion Criteria: PSA >5 ng/ml. For men with prior radical prostatectomy: PSA-DT < 1 year or pathological ISUP grade 4-5 For men with prior radiation therapy: Interval to biochemical recurrence < 18 months or biopsy ISUP grade 4-5 Other malignancy within the last 2 years except: adequately treated non-melanoma skin cancer and low-grade non-muscle invasive papillary bladder cancer. Concurrent or previous treatment within 30 days in another interventional clinical trial with an investigational anticancer therapy Patients who are receiving androgen-deprivation therapy. Patients who have received prior Androgen Deprivation Therapy (ADT) are not eligible with the exception of those that received ADT ≤ 36 months in duration and ≥9 months before enrolment and administered only in the neoadjuvant/adjuvant setting. Castrate level of serum testosterone <50 ng/dL at screening. History of HIV infection Viral active or chronic hepatitis (HBV or HCV) Ongoing autoimmune disease Current relevant central nervous system pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder) Therapeutic anticoagulation Non-controlled hypertension, defined as mean blood pressure values in 24-hours blood pressure measurement of >130 mmHg or >90 mmHg for systolic or diastolic, respectively Heart failure defined as New York Heart Association (NYHA) III/IV Severe obstructive or restrictive ventilation disorder Known intolerance to CC-1 or other immunoglobulin drug products as well as hypersensitivity to any of the excipients present in CC-1